Oxford Biomedical Research, Inc. has been awarded a Phase II Small Business Innovation Research Grant by the National Institute of Environmental Health Sciences. The grant, valued at $1.2 million, is for the development of a panel of tests designed to use GST proteins as more sensitive and specific biomarkers to detect toxicity and differentiate potential toxic effects to multiple organs.
GST proteins, found in many tissues and organs, play an important role in the elimination of drugs and environmental compounds that humans are exposed to and are considered extremely sensitive biomarkers for toxicity.
Researchers at Oxford Biomedical Research have already assembled tests for a number of GST proteins. The NIH-funded research includes development of a device that can rapidly and inexpensively measure multiple GSTs. The utility of GSTs for organ-specific toxicity testing will be validated by comparison to conventional toxicity tests used during drug development and in the clinic.
Oxford Biomedical Awarded NIH Grant
By Kristin Brooks
Published December 10, 2013
blog comments powered by Disqus